Advanced Lipid Panel, Cardio IQ Test

Every atherogenic lipoprotein in the low-density range carries a single apolipoprotein B molecule, so a direct count of these particles reports how many cholesterol-carrying vehicles are circulating rather than how much cholesterol they hold. Particle number and cholesterol content track together in most patients, but hepatic lipid handling, insulin resistance, and triglyceride enrichment can uncouple them, producing many small cholesterol-poor particles that a standard cholesterol measurement understates.

LDL-P quantifies the atherogenic particle burden that drives arterial intimal retention, and it is most informative when it is read against LDL-C and the rest of the panel rather than alone. The decisive scenario is discordance: when particle number sits higher than the cholesterol concentration predicts, residual risk is underestimated by LDL-C, and the particle count reclassifies the patient upward. It is interpreted together with apolipoprotein B, which it closely parallels.

Apolipoprotein B-100 is the single structural protein of VLDL, IDL, LDL, and lipoprotein(a), present as one copy per particle, so its serum concentration is a near-direct census of atherogenic lipoproteins. Because it is measured by immunoassay rather than calculated, apoB sidesteps the assumptions that degrade a computed LDL-C when triglycerides are high or cholesterol is unevenly distributed across particles.

ApoB is increasingly positioned as the preferred single measure of atherogenic lipoprotein burden and, like LDL-P, earns its value where it diverges from LDL-C. In insulin resistance, hypertriglyceridaemia, and metabolic syndrome a patient can carry a reassuring LDL-C alongside a high apoB, and the protein concentration captures the residual risk the cholesterol number misses. It is read in concert with the full panel, not as a standalone verdict.

LDL-C is the mass of cholesterol carried within low-density lipoproteins. On advanced panels it is frequently measured directly or calculated by a validated equation rather than by the older Friedewald formula, which loses reliability at high triglycerides or low cholesterol. It reflects cholesterol quantity, which is not always proportional to the number of particles delivering it.

LDL-C remains the anchor of cardiovascular risk assessment and the primary treatment target in most guidelines, and it carries the largest trial evidence base for intervention. Its limitation, and the reason the particle measures sit beside it on this panel, is that it reports cholesterol content rather than particle count; when the two disagree the particle-based markers refine the estimate. It is never interpreted in isolation here.

HDL-C measures cholesterol within high-density lipoproteins, the particles central to reverse cholesterol transport and to anti-inflammatory and antioxidant functions in the vessel wall. The cholesterol mass is an imperfect surrogate for HDL functionality, and very high concentrations do not confer proportionally greater protection.

HDL-C is read as a risk modifier and as an input to non-HDL cholesterol rather than as a therapeutic target, since trials raising HDL-C pharmacologically have not reduced events. On this panel its main role is to be subtracted from total cholesterol to yield the non-HDL figure and to flag the low-HDL, high-triglyceride pattern of insulin resistance, interpreted alongside the atherogenic markers.

Triglycerides circulate chiefly in chylomicrons and VLDL and reflect dietary fat handling, hepatic VLDL output, and the efficiency of lipoprotein lipase clearance. Fasting concentrations are strongly influenced by recent meals, alcohol, and carbohydrate load, which is the principal reason this panel is drawn fasting.

Triglycerides mark the triglyceride-rich lipoprotein remnants that contribute to atherogenesis and signal the metabolic syndrome phenotype. They are interpreted together with HDL-C and the particle measures: a high triglyceride with normal LDL-C is the classic setting in which LDL-P and apoB are discordantly elevated. Very high values additionally raise concern for pancreatitis rather than for cardiovascular risk alone.

Lipoprotein(a) is an LDL-like particle in which apolipoprotein(a) is linked to apolipoprotein B-100. Its concentration is largely genetically determined by the LPA gene, remains stable across the lifespan, and is minimally responsive to diet, exercise, or statin therapy, so a single measurement is generally sufficient.

Lp(a) is an independent, causal, and heritable risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis, and it explains residual risk that the cholesterol and particle measures do not capture. It is interpreted as a one-time genetic risk descriptor that modifies the intensity of management of the other, more modifiable markers on the panel, rather than as a treatment target in itself at present.

Non-HDL cholesterol is a derived value: total cholesterol minus HDL-C. It sums the cholesterol carried by every apoB-containing particle — LDL, VLDL, IDL, remnants, and lipoprotein(a) — so it approximates the full atherogenic burden without requiring an additional assay and without the triglyceride-dependent error of a calculated LDL-C.

Non-HDL-C is a robust secondary target that often outperforms LDL-C in patients with hypertriglyceridaemia or diabetes, bridging the gap between the cholesterol-based and particle-based views of risk. It is computed from values already on this panel and is interpreted alongside apoB and LDL-P as a convergent estimate of atherogenic load.